Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
NLRP3
Biotech
Neurocrine pens $880M pact with TransThera for immunology target
San Diego-based Neurocrine secured the rights to develop and commercialize preclinical NLRP3 inhibitors.
James Waldron
Nov 3, 2025 5:42am
Ventyx posts Parkinson's data ahead of potential Sanofi talks
Jun 17, 2025 9:05am
NodThera's NLRP3 inhibitor shows obesity promise in early trial
Jun 12, 2024 7:00am
NodThera's NLRP3 inhibitor nearly matches Wegovy for weight loss
Feb 21, 2024 8:30am
Novo enters NLRP3 arena, paying Ventus $70M for NASH hopeful
Sep 29, 2022 9:30am
